Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6482 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD6482 on top of ASA |
| 2 | ACTIVE_COMPARATOR | Clopidogrel on top of ASA |
| Name | Type | Description |
|---|---|---|
| AZD6482 | DRUG | Single intravenous infusion during a maximum of 5 hours |
| Clopidogrel | DRUG | Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7. |
| ASA | DRUG | 75 mg orally once daily during 7 days in each treatment arm |
| Placebo | DRUG | - |
Inclusion Criteria: * BMI between 19.0 and 30.0 kg/m2, inclusive and body weight between 50.0 and 100.0 kg, inclusive * Provision of written informed consent Exclusion Criteria: * Personal or family history of bleeding disorders, or reasonable suspicion of vascular malformations, including aneury...
AZD6482 is an investigational small molecule being studied for its antiplatelet effect, meaning it is intended to reduce the ability of blood platelets to clump together and form clots. It is being developed by AstraZeneca PLC and is currently in Phase 1 clinical development.
AZD6482 is a small molecule designed to produce an antiplatelet effect, which involves inhibiting platelet aggregation. The specific molecular target of AZD6482 has not been disclosed in the available information, so its exact mechanism of action is not detailed here.
AZD6482 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical trials, and AstraZeneca is responsible for its research and development.
AZD6482 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety, tolerability, and effects in humans.
AZD6482 has been studied in two completed Phase 1 clinical trials. The first, NCT00688714, investigated the safety and tolerability of a single dose in 49 healthy male volunteers. The second, NCT00853450, was a bleeding time study comparing AZD6482 with clopidogrel and aspirin in 28 healthy male volunteers in Sweden.
No, AZD6482 is not the same as clopidogrel or aspirin. In a clinical trial (NCT00853450), AZD6482 was studied alongside clopidogrel and aspirin to compare their effects on bleeding time, but AZD6482 is a distinct investigational compound with its own antiplatelet properties.